TerminatedNot Applicable

SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation

Stopped: poor enrollment (only one subject enrolled)

United States1 participantsStarted 2011-09

Plain-language summary

The purpose of this study is to determine if simvastatin improves development and behavior in patients with Smith Lemli-Opitz syndrome (SLOS) receiving dietary cholesterol supplementation.

Who can participate

Age range1 Year – 89 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female over 1 years old * Subject has confirmed diagnosis of Smith-Lemli-Opitz Syndrome * Subject is currently receiving cholesterol supplementation Exclusion Criteria: * Subjects too ill to travel to the study site * Subjects who are unable to safely undergo study procedures * Pregnant women

What they're measuring

Development Quotient (DQ)

Timeframe: through study completion, an average of 2 per year

Trial details

NCT IDNCT01434745

SponsorOregon Health and Science University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-10

Results submitted2019-09-12

View on ClinicalTrials.gov More Smith-Lemli-Opitz Syndrome trials